Precipio, Inc. (PRPO)

Market Cap	45.61M +314.6%
Revenue (ttm)	25.83M +29.0%
Net Income	-922,000
EPS	-0.55
Shares Out	1.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,751
Open	24.66
Previous Close	24.95
Day's Range	23.97 - 26.60
52-Week Range	7.52 - 33.63
Beta	1.38
Analysts	Strong Buy
Price Target	19.00 (-25.65%)
Earnings Date	May 14, 2026

About PRPO

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

• Industry: Diagnostics & Research
• Sector: Healthcare
• CEO: Ilan Danieli
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: PRPO
• Website: https://www.precipiodx.com

Financial Performance

In 2025, Precipio's revenue was $24.05 million, an increase of 29.77% compared to the previous year's $18.53 million. Losses were -$363,000, -91.54% less than in 2024.

Analyst Summary

According to one analyst, the rating for PRPO stock is "Strong Buy" and the 12-month stock price target is $19.0.

Price Target

$19.0

(-25.65% downside)

Analyst Consensus: Strong Buy